Scientific Publications
Claims-based prediction models commonly use dichotomous indicator variables (e.g., presence/absence of disease) or count variables (e.g., frequency of claims) as predictors. The research objective was to compare the predictive ability of this standard model with other models that account for the sequence of events. The models were applied in the context of predicting hypoparathyroidism diagnosis among Medicare beneficiaries.
Authors
Site Li, Bingqing Yu, Xinyi Wang, Guangyan Yu, Diptanshu Singh, Gavin Miyasato, Masanao Yajima
Journal
ISPOR Meeting, May 2019
View publication…
Read Now
Scientific Publications
The objective is to understand the unmet needs related to the diagnosis and management of patients with hypoactive sexual desire disorder (HSDD).
Authors
Sharon Parish, Zainab Shahpurwala, Rahul Ravindranath, Amod Athavale, Nandini Hadker, and Michelle Lim-Watson
Journal
ISPOR Meeting, May 2019
View publication…
Read Now
Scientific Publications
The purpose of this study was to systematically assess rates of treatment-emergent hypophosphatemia among IDI formulations used in IDA.
Authors
Lim-Watson M, Libre M, Karkare S, Alkhateeb Z, Hadker N, Bajic-Lucas A, Dahl N, Strauss W, Glaspy J
Journal
ISPOR Meeting, May 2019
View publication…
Read Now
Scientific Publications
Obesity is a disease that is caused and influenced by genes and the environment. Whether different etiologies or presentations of obesity result in homogeneous disease burden and/or cost is not well characterized.
The objective is to determine whether there are distinct segments within the pool of patients who are obese that are differentiated by clinical characteristics, and quantify their healthcare resource utilization (direct healthcare costs [HCC]), using U.S. claims data.
Authors
Marissa Suh, Monica Fay, Amy McCagg, Ida Moeller, Scott…
Read Now
White Papers
Pharma and biotech companies are innovation drivers at the frontlines of research and development. To fund and support this promising science, there is a great need for partnerships and mergers and acquisitions (M&A) to drive the growth/pipeline of the industry. For these collaborative relationships to occur, understanding the value of a company’s underlying assets is of the utmost importance.
Since Trinity’s founding, multiple pharma and biotech clients have relied on its expertise in forecast and valuing assets. These engagements have…
Read Now
